Krsnaa Diagnostics working capital

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

57.22×	57.22×	70.39×	78.78×	123.38×	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
135.38×	135.38×	115.54×	73.45×	54.77×
163.42×	163.42×	193.48×	186.90×	305.69×
29.18×	29.18×	−7.55×	−34.67×	−127.54×
1.76×	1.67×	6.57×	4.43×	3.85×
0.50×	0.50×	0.58×	0.60×	0.55×
1.41×	1.41×	1.13×	0.43×	1.23×
0.68×	0.68×	0.46×	0.17×	0.62×

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

KRSNAA₹497.95

Krsnaa Diagnostics Limited

· Pharma & Health

₹ CrorePeersSURAKSHA HEALTHX NEPHROPLUS 3BBLACKBIOMcap ₹1,615 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Inventory Days (DIO)	123.38	78.78	70.39	57.22	57.22
Receivable Days (DSO)	54.77	73.45	115.54	135.38	135.38
Payable Days (DPO)	305.69	186.90	193.48	163.42	163.42
Cash Conversion Cycle (days)	-127.54	-34.67	-7.55	29.18	29.18
Working Capital Turnover	3.85	4.43	6.57	1.67	1.76
Asset Turnover	0.55	0.60	0.58	0.50	0.50
Cash Conversion (CFO/Net Income)	1.23	0.43	1.13	1.41	1.41
CFO/EBITDA	0.62	0.17	0.46	0.68	0.68

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.